Suven Pharma has demonstrated strong financial metrics, underscoring its operational efficiency and market competitiveness. As of Q3 FY2024-2025, the company reported a revenue of ₹322.86 crore, marking a 37.88% year-over-year increase. Net profit for the same period stood at ₹82.88 crore, reflecting a 77.28% growth compared to the previous year The company's return on equity (ROE) has been consistently robust, with a three-year average of 21.9%. Additionally, Suven maintains a low debt-to-equity ratio of 0.01, indicating prudent financial management.